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ABSTRACT
OBJECTIVES The aim of this study was to assess safety outcomes of femoropopliteal drug-coated balloon (DCB)
angioplasty using patient-level data from the Lutonix clinical program.
BACKGROUND A recent systematic review and meta-analysis of heterogenous trials and summary-level data identified
increased long-term mortality in patients treated with paclitaxel-coated balloons and stents.
METHODS We evaluated DCB angioplasty (n ¼ 1,093) and uncoated balloon angioplasty (percutaneous transluminal
angioplasty [PTA]) (n ¼ 250) outcomes in LEVANT 1 (The Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropopliteal Restenosis), LEVANT 2 (Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment
of Femoropopliteal Arteries), and the LEVANT Japan Clinical Trial. Hazard ratios (HRs) were calculated with Cox pro-
portional hazards modeling.
RESULTS There were no significant differences in mortality rates between DCB angioplasty and PTA. The 5-year HR was
1.01 (95% confidence interval [CI]: 0.68 to 1.52) in the aggregated LEVANT trials. The 2-year HR after DCB angioplasty
was 0.99 (95% CI: 0.25 to 3.95) in LEVANT 1, 1.40 (95% CI: 0.62 to 3.14) in LEVANT 2, and 0.32 (95% CI: 0.05 to 1.92)
in the LEVANT Japan Clinical Trial. The 5-year HR was 1.60 (95% CI: 0.94 to 2.72) in LEVANT 2. Adverse events and
causes of death were balanced, without clustering between DCB angioplasty and PTA. Patients who underwent paclitaxel
or nonpaclitaxel reinterventions had higher survival rates than those who did not undergo reinterventions. Baseline
covariates predicting mortality included, among others, age (HR: 1.03 per year; p < 0.0001), prior treatment of target
lesion (HR: 1.67; p ¼ 0.022), arrhythmia (HR: 1.65; p ¼ 0.031), and diabetes (HR: 1.18; p ¼ 0.047), without differences
between the 2 arms. No dose-response relationship was identified when adjusted for key predictors of mortality.
CONCLUSIONS Analyses of patient-level data identified no mortality differences between DCB angioplasty and PTA.
Furthermore, the lack of dose-response relationships or clustering of causes of death argues against a causal relationship
between paclitaxel and mortality. (LEVANT 1, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropo-
pliteal Restenosis [LEVANT 1], NCT00930813; Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the
Treatment of Femoropopliteal Arteries [LEVANT 2], NCT01412541; LEVANT 2 Continued Access Registry, NCT01628159;
LEVANT Japan Clinical Trial, NCT01816412) (J Am Coll Cardiol Intv 2019;12:2515–24) © 2019 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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L ower extremity peripheral arterydisease (PAD) is an increasingly prev-alent global health concern, associ-
ated with a 3- to 5-fold increase in mortality
risk over that of the general population
(1,2). Although endovascular or open surgical
revascularization is recommended for pa-
tients with symptomatic femoropopliteal
PAD, there remains no consensus on the
optimalstrategyfor thispatientpopulation(3).
Traditional therapies for femoral popliteal
PAD include uncoated balloon angioplasty
(percutaneous transluminal angioplasty [PTA]), stent
placement, and atherectomy (4). In this landscape,
drug-eluting stents (DES) and drug-coated balloons
(DCBs) were developed, using antiproliferative agents
such as paclitaxel, a commonly used cancer chemo-
therapeutic agent. Although evidence documented
markedly improved patency rates after treatment of
femoropopliteal lesions with DES and DCBs compared
with PTA (5–8), a recent systematic review and meta-
analysis by Katsanos et al. (9) identified an increased
mortality signal associated with the use of paclitaxel
devices for femoropopliteal PAD.
The present review was undertaken to assess mor-
tality after DCB treatment of femoropopliteal disease,
using independent patient-level data from the Lutonix
clinical program. The availability of independent
patient-level data from the Lutonix clinical program
allowed a granularity of analysis not possible with
research-derived data from meta-analyses.
METHODS
DATA SOURCES. The analyses comprised the 3
randomized controlled trials in the Lutonix
femoropopliteal clinical program, LEVANT 1 (The
Lutonix Paclitaxel-Coated Balloon for the Prevention
of Femoropopliteal Restenosis), LEVANT 2 (Moxy
Drug Coated Balloon vs. Standard Balloon Angio-
plasty for the Treatment of Femoropopliteal Arteries),
and the LEVANT Japan Clinical Trial, and the single-
arm continued-access arm of the LEVANT 2 trial
(Table 1). These studies are a subset of the 3,095 pa-
tients treated in the Lutonix global femoropopliteal
clinical program that enrolled 2,845 patients (91.9%)
treated with the Lutonix DCB and 250 (8.1%) with
uncoated PTA. The primary analysis focused on the
LEVANT 2 randomized trial, the largest of the ran-
domized trials with the longest follow-up duration,
spanning 5 years. The LEVANT 1, LEVANT Japan
Clinical Trial, and LEVANT 2 Continued Access Reg-
istry cohorts were used to identify predictors of
mortality and to assess the effect of additional study
data on mortality outcomes. All analyses were done
on an intention-to-treat basis.
INTERVENTIONAL TECHNIQUE. The Lutonix DCB is
intended to treat de novo or restenotic lesions within
the superficial femoral or popliteal arteries. The DCB
is mounted on a 0.035-inch over-the-wire catheter
with a proximal manifold. The surface concentration
of paclitaxel is 2 mg/mm2, and the dose of paclitaxel
delivered was calculated by multiplying the surface
concentration by the surface area of the balloon that
comes in contact with the vessel. The instructions for
use recommend vessel preparation of the target
lesion using pre-dilation with an uncoated angio-
plasty balloon. A minimum inflation time of 120 s is
recommended for the Lutonix DCB.
STUDY ENDPOINTS. All deaths were originally adju-
dicated by a blinded, independent, clinical events
committee composed of varied specialists. As part of
the current meta-analysis, causes of death in the
SEE PAGE 2525
ABBR EV I A T I ON S
AND ACRONYMS
CI = confidence interval
DCB = drug-coated balloon
DES = drug-eluting stent(s)
HR = hazard ratio
PAD = peripheral artery
disease
PTA = percutaneous
transluminal angioplasty
SAE = serious adverse event
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LEVANT 1 and LEVANT 2 trials were readjudicated by
an independent ad hoc adjudication committee
comprising vascular surgeons, interventional radiol-
ogists, and oncologists with systemic paclitaxel
chemotherapy knowledge. Deaths in the LEVANT
Japan Clinical Trial were not readjudicated, because
of unavailability of original source documents and
translations. A 2 þ 1 adjudication model and an elec-
tronic adjudication system (Syncrony, Syntactx, New
York, New York) was used. In a 2 þ 1 adjudication
model, an interventionalist and an oncologist blinded
to treatment, DCB angioplasty or PTA, separately
adjudicated the elements of each events. If any
element of an adjudication was discordant between
the 2 adjudicators, the discordant elements were
submitted to a tiebreaking adjudicator, who was al-
ways an oncologist.
Deaths in the LEVANT 1 and LEVANT 2 trials were
classified by their relationship to the device, pro-
cedure, and paclitaxel. They were also categorized as
cardiovascular or noncardiovascular. Cardiovascular
deaths were further subcategorized according to eti-
ology, namely, acute myocardial infarction, sudden
cardiac death, heart failure, stroke, cardiovascular
procedures, cardiovascular hemorrhage, or other
cardiovascular causes, using the guidelines estab-
lished by Hicks et al. (10). Noncardiovascular deaths
were subcategorized and included pulmonary, renal,
gastrointestinal, hepatobiliary, pancreatic, infectious
or inflammatory, hemorrhagic, procedural, trauma,
suicide, drug reaction (prescription and nonpre-
scription), neurological (excluding cardiovascular
neurological deaths), malignancy, and other non-
cardiovascular deaths. If the adjudicator could not
determine if a death was cardiovascular or non-
cardiovascular, the death was classified as undeter-
mined. Paclitaxel relatedness was adjudicated on the
basis of known complications associated with the
drug and a full review of all reported adverse events
between enrollment and death, allowing flexibility
for adjudicators to assign paclitaxel relatedness for
mechanisms yet undescribed for paclitaxel. The
deaths were also classified by the Medical Dictionary
for Regulatory Activities version 2.10 (MedDRA
MSSO, McLean, Virginia) using system organ
classifications.
STATISTICAL ANALYSIS. To create commonality of
variables, the datasets from individual trials were
combined into analytic databases after mapping the
variables using R version 3.5.2 (R Project for Statisti-
cal Computing, Vienna Austria). Statistical analyses
were performed using SAS version 9.4 (SAS Institute,
Cary, North Carolina) and Stata/IC version 15.1
(StataCorp, College Station, Texas). All analyses were
performed by an independent clinical research orga-
nization (Syntactx).
Comparisons of categorical data were done using
the Fisher exact test. Comparisons of continuous
variables were performed using Student’s t-test.
Freedom from all-cause mortality was estimated for
each trial using Kaplan-Meier methodology. Differ-
ences were tested using the log-rank test.
The Cox proportional hazards model was used to
predict survival up to 5 years. Patients were censored
at the time of death, at the date of last contact, or at 5
years, whichever came first. A time-dependent co-
variate was created when a post-index procedure
reintervention was performed on the femoropopliteal
vessels of either leg, subcategorized by whether the
reintervention was with a paclitaxel-containing de-
vice. Models exploring the time-dependent relation-
ship of reinterventions included treatment arm
(DCB angioplasty vs. PTA) as a baseline covariate. Cox
TABLE 1 Global Lutonix Femoropopliteal Clinical Program
Drug per mm2
ClinicalTrials.gov
Identifier Enrollment Start Study Design
Subjects Included
(DCB Angioplasty/PTA) Geography
Follow-Up
(Months)
LEVANT 1 2 NCT00930813 June 2009 RCT 101 (49/52) Europe 24
LEVANT 2 pivotal with roll-in DCB 2 NCT01412541 July 2011 RCT 532 (316/160)* United States 60
LEVANT 2 (Continued
Access Registry)
2 NCT01628159 February 2013 Single arm 657 United States, Europe 60
LEVANT Japan Clinical Trial 2 NCT01816412 March 2013 RCT 109 (71/38) Japan 24
SAFE-DCB U.S. registry 2 NCT02424383 April 2015 Single arm 1,005 United States 36
Lutonix Global SFA Registry 2 NCT01864278 December 2012 Single arm 691 Europe 24
Total 3,095 (2,845/250) Europe, United States,
Japan
24–60
*There were 56 roll-in subjects treated with DCBs.
DCB ¼ drug-coated balloon; LEVANT 1 ¼ The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis; LEVANT 2 ¼Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty
for the Treatment of Femoropopliteal Arteries; PTA ¼ percutaneous transluminal angioplasty; RCT ¼ randomized controlled trial; SAFE-DCB ¼ Real-World Registry Assessing the Clinical Use of the Lutonix
035 Drug Coated Balloon Catheter; SFA ¼ superficial femoral artery.
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proportional hazards modeling was used to identify
predictors of time to adverse events, time to serious
adverse events (SAEs), and time to death.
RESULTS
DEMOGRAPHIC AND BASELINE CHARACTERISTICS.
The demographic and baseline characteristics were
comparable in patients treated with DCB angioplasty
and PTA in the LEVANT trials (Table 2). Patients in the
LEVANT 2 study were largely men (DCB angioplasty,
61.1%; PTA, 66.9%), and the most common comor-
bidities were hypertension, dyslipidemia, and
myocardial infarction. Approximately 80% of DCB
and PTA patients were current or former smokers.
The average target lesion length was 62.1  41.6 mm
in the DCB group and 62.3  40.9 mm in the PTA
group (Table 3). Most target lesions were de novo
(DCB, 87.7%; PTA, 91.9%), and calcification was re-
ported in 59.2% of DCB patients and 58.1% of PTA
patients. The most common baseline Rutherford
category was 3 (DCB, 62.7%; PTA, 57.5%), and the
average ankle brachial index was 0.7  0.2 in both
groups. Patients in the DCB arm received a mean
paclitaxel dose of 3.6  1.9 mg at the index procedure.
SURVIVAL ANALYSES. A survival analysis of LEVANT
2 revealed a numerically higher 5-year survival in the
TABLE 2 Baseline and Demographic Characteristics of Patients in the Randomized Trials
LEVANT 1 RCT LEVANT 2 RCT LEVANT 2 CAR LEVANT Japan Clinical Trial
DCB Angioplasty
(n ¼ 49)
PTA
(n ¼ 52)
DCB Angioplasty
(n ¼ 316)
PTA
(n ¼ 160)
DCB Angioplasty
(n ¼ 657)
DCB Angioplasty
(n ¼ 71)
PTA
(n ¼ 38)
Age, yrs 66.7  8.4 69.9  9.6 67.6  10.0 68.8  9.0 68.5  9.6 72.5  9.8 78.2  8.1
p ¼ 0.073 p ¼ 0.197 p ¼ 0.002
Male 69.4 (34/49) 57.7 (30/52) 61.1 (193/316) 66.9 (107/160) 63.8 (419/657) 63.4 (45/71) 68.4 (26/38)
p ¼ 0.302 p ¼ 0.229 p ¼ 0.676
Medical history
Arrhythmia 16.3 (8/49) 17.3 (9/52) 10.4 (33/316) 14.4 (23/160) 11.7 (77/657) 8.5 (6/71) 10.5 (4/38)
p > 0.999 p ¼ 0.229 p ¼ 0.737
Hypertension 35.9 (47/49) 86.5 (45/52) 89.2 (282/316) 87.5 (140/160) 88.0 (578/657) 84.5 (60/71) 92.1 (35/38)
p ¼ 0.162 p ¼ 0.647 p ¼ 0.371
Dyslipidemia 59.2 (29/49) 69.2 (36/52) 89.6 (283/316) 86.3 (138/160) 83.7 (550/657) 66.2 (47/71) 68.4 (26/38)
p ¼ 0.308 p ¼ 0.291 p > 0.999
Myocardial infarction 15.8 (3/19) 47.8 (11/23) 40.1 (63/157) 35.9 (28/78) 44.7 (143/320) 32.3 (10/31) 35.7 (5/14)
p ¼ 0.048 p ¼ 0.571 p > 0.999
Angina 10.5 (2/19) 13.0 (3/23) 21.0 (33/157) 19.2 (15/78) 28.4 (91/320) 61.3 (19/31) 85.7 (12/14)
p > 0.999 p ¼ 0.864 p ¼ 0.165
Congestive heart failure 8.2 (4/49) 7.7 (4/52) 5.7 (18/316) 3.1 (5/160) 7.0 (46/657) 4.2 (3/71) 15.8 (6/38)
p > 0.999 p ¼ 0.263 p ¼ 0.063
Renal failure 20.4 (10/49) 32.7 (17/52) 3.5 (11/316) 4.4 (7/160) 8.8 (58/657) 7.0 (5/71) 5.3 (2/38)
p ¼ 0.184 p ¼ 0.619 p > 0.999
CVA 10.2 (5/49) 9.6 (5/52) 11.4 (36/316) 11.3 (18/160) 10.5 (69/657) 18.3 (13/71) 23.7 (9/38)
p > 0.999 p > 0.999 p ¼ 0.617
Diabetes 44.9 (22/49) 50.0 (26/52) 43.4 (137/316) 41.9 (67/160) 36.7 (241/657) 46.5 (33/71) 47.4 (18/38)
p ¼ 0.691 p ¼ 0.770 p > 0.999
Prior revascularization* 65.3 (32/49) 53.9 (28/52) 66.1 (209/316) 69.1 (101/160) 62.7 (412/657) 47.9 (34/71) 50.0 (19/38)
p ¼ 0.311 p ¼ 0.542 p ¼ 0.844
Statins 73.5 (36/49) 67.3 (35/52) 77.2 (244/316) 78.8 (126/160) 73.5 (483/657) 53.5 (38/71) 55.3 (21/38)
p ¼ 0.522 p ¼ 0.728 p > 0.999
Smoking
Current 30.6 (15/49) 38.5 (20/52) 35.1 (111/316) 33.8 (54/160) 35.8 (235/657) 21.1 (15/71) 26.3 (10/38)
p ¼ 0.531 p ¼ 0.839 p ¼ 0.634
Previous 36.7 (18/49) 30.8 (16/52) 44.0 (139/316) 48.8 (78/160) 46.3 (304/657) 53.5 (38/71) 42.1 (16/38)
p ¼ 0.536 p ¼ 0.332 p ¼ 0.316
Never 32.7 (16/49) 30.8 (16/52) 20.9 (66/316) 17.5 (28/160) 18.0 (118/657) 23.4 (18/71) 31.6 (12/38)
p > 0.999 p ¼ 0.397 p ¼ 0.507
Values are mean  SD or % (n/n). *Refers to peripheral revascularization.
CAR ¼ Continued Access Registry; CVA ¼ cerebrovascular accident; other abbreviations as in Table 1.
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PTA arm (87.7  2.7%) compared with the DCB arm
(80.8  2.3%), but the difference did not attain sta-
tistical significance (p ¼ 0.084). The 2-year hazard
ratio (HR) after DCB angioplasty was 0.99 (95% con-
fidence interval [CI]: 0.25 to 3.95) in LEVANT 1, 1.40
(95% CI: 0.62 to 3.14) in LEVANT 2, and 0.32 (95% CI:
0.05 to 1.92) in the LEVANT Japan Clinical Trial. The
LEVANT 2 randomized trial HR for all-cause mortal-
ity increased from 1.13 (95% CI: 0.35 to 3.68;
p ¼ 0.834) at 1 year to 1.60 (95% CI: 0.94 to 2.72;
p ¼ 0.084) at 5 years. The HR was 1.25 (95% CI: 0.765
to 2.045; p ¼ 0.3715) at 5 years in the LEVANT 2
combined randomized and Continued Access Regis-
try DCB cohorts versus PTA. Survival differences
between DCB angioplasty and PTA diminished as
data from the trials were aggregated. The HR was 1.01
(95% CI: 0.68 to 1.52; p ¼ 0.95) through 5 years
(including all visits) in the aggregated analysis
dataset of LEVANT 1, LEVANT 2, and the LEVANT
Japan Clinical Trial (Central Illustration). The median
follow-up duration for the 3 studies was 1,779 days
(interquartile range: 892 to 1,847 days).
When the HR was adjusted for post-procedural
reinterventions as a time-dependent covariate, the
resulting 1-year HR was 0.99 (95% CI: 0.30 to 3.28),
and the 5-year HR was 1.64 (95% CI: 0.95 to 2.82).
The 5-year HR was unchanged when adjusted for
post-procedural reinterventions with paclitaxel-
containing devices as a time-dependent covariate
(at 5 years, HR: 1.65; 95% CI: 0.95 to 2.84).
CLUSTERING OF DEATH AND ADVERSE EVENTS.
The causes of death are summarized in Table 4, as
adjudicated by the independent committee. Among
the 173 deaths in LEVANT 1 and LEVANT 2 (including
the Continued Access Registry patients), 151 occurred
in DCB patients (14.0%) and 22 in PTA patients
(10.4%). Among these, none were adjudicated as
related to paclitaxel.
There was no clustering of deaths in any category;
differences in the proportion of deaths of any 1 cate-
gory within the DCB or the PTA cohorts were not
statistically significant. Patients died of cardiovascu-
lar causes in 5.1% (55 of 1,078) and 3.8% (8 of 212) of
the DCB and PTA groups, respectively (p ¼ 0.489).
TABLE 3 Target Lesion Characteristics and Paclitaxel Dose in the Randomized Trials
LEVANT 1 RCT LEVANT 2 RCT LEVANT 2 CAR LEVANT Japan Clinical Trial
DCB Angioplasty PTA DCB Angioplasty PTA DCB Angioplasty DCB Angioplasty PTA
Rutherford category
2 0.0 (0/49) 0.0 (0/52) 29.4 (93/316) 34.4 (55/160) 36.5 (240/657) 59.2 (42/71) 55.3 (21/38)
p ¼ 0.295 p ¼ 0.839
3 22.5 (11/49) 21.2 (11/52) 62.7 (198/316) 57.5 (92/160) 57.7 (379/657) 40.9 (29/71) 42.1 (16/38)
p > 0.999 p ¼ 0.276 p > 0.999
4 71.4 (35/49) 71.2 (37/52) 7.9 (25/316) 8.1 (13/160) 5.8 (38/657) 0.0 (0/71) 2.6 (1/38)
p > 0.999 p > 0.999 p ¼ 0.349
5 2.0 (1/49) 3.9 (2/52) 0.0 (0/316) 0.0 (0/160) 0.0 (0/657) 0.0 (0/71) 0.0 (0/38)
p > 0.999
6 4.1 (2/49) 3.9 (2/52) 0.0 (0/316) 0.0 (0/160) 0.0 (0/657) 0.0 (0/71) 0.0 (0/38)
p > 0.999
Lesion
De novo 89.4 (42/47) 88.5 (46/52) 87.7 (277/316) 91.9 (147/160) 90.6 (595/657) 95.8 (68/71) 94.7 (36/38)
p > 0.999 p ¼ 0.213 p > 0.999
Recurrent 10.6 (5/47) 11.5 (6/52) 12.3 (39/316) 8.1 (13/160) 9.4 (62/657) 4.2 (3/71) 5.3 (2/38)
p > 0.999 p ¼ 0.213 p > 0.999
Calcification (% of patients) NA 59.2 (187/316) 58.1 (93/160) 66.2 (435/657) 46.5 (33/71) 60.5 (23/38)
p ¼ 0.844 p ¼ 0.228
Ankle-brachial index 0.8  0.2 0.8  0.3 0.7  0.2 0.7  0.2 0.7  0.3 0.7  0.1 0.7  0.1
p ¼ 0.374 p ¼ 0.825 p ¼ 0.908
Total lesion length, mm 88.1  36.8 86.2  38.1 62.1  41.6 62.3  40.9 53.9  40.7 67.7  43.5 55.3  51.0
p ¼ 0.7980 p ¼ 0.949 p ¼ 0.208
Reference vessel diameter, mm 5.0  0.6 5.2  0.6 4.8  0.8 4.8  0.8 4.8  0.8 4.9  0.7 4.7  0.7
p ¼ 0.096 p ¼ 0.993 p ¼ 0.397
Maximum diameter stenosis, % 89.0  9.8 90.1  11.1 80.3  14.8 80.8  14.9 82.2  13.8 80.9  14.8 78.3  13.2
p ¼ 0.607 p ¼ 0.709 p ¼ 0.357
Mean paclitaxel dose, mg 2.8  0.7 NA 3.6  1.9 NA 3.5  1.8 2.0  0.9 NA
Values are mean  SD or % (n/N).
NA ¼ not applicable; other abbreviations as in Tables 1 and 2.
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CENTRAL ILLUSTRATION Lutonix Drug-Coated Balloon and Study Outcome
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Ouriel, K. et al. J Am Coll Cardiol Intv. 2019;12(24):2515–24.
(A) Components of the Lutonix drug-coated balloon (DCB). The Lutonix balloon, indicated for the treatment of peripheral artery disease, is
coated with paclitaxel to prevent vessel restenosis. (B) Survival in LEVANT 1 (The Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropopliteal Restenosis), LEVANT 2 (Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal
Arteries), and LEVANT Japan Clinical Trial. Aggregated survival outcomes from the 3 trials show comparable 5-year survival rates in the
percutaneous transluminal angioplasty (PTA) and DCB angioplasty groups.
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Noncardiovascular deaths occurred in 7.3% (79 of
1,078) and 5.2% (11 of 212) of the DCB and PTA groups
(p ¼ 0.304). There was no difference in the proportion
of deaths of undetermined cause in the 2 groups, 1.6%
(17 of 1,078) in the DCB group versus 1.4% (3 of 212) in
the PTA group (p > 0.999).
Cardiovascular deaths were balanced in the DCB
and PTA groups. The most common subtypes were
heart failure, occurring in 1.9% (21 of 1,078) and 1.4%
(3 of 212) of the DCB and PTA groups, respectively
(p ¼ 0.784), followed by acute myocardial infarction,
occurring in 1.3% (14 of 1,078) of the DCB group and
0.9% (2 of 212) of the PTA group (p > 0.999). Non-
cardiovascular deaths were also balanced in the 2
groups. Among subtypes of noncardiovascular
deaths, neoplasm predominated; 4.5% (48 of 1,078) in
the DCB group versus 3.3% (7 of 212) in the PTA group
(p ¼ 0.577). Among neoplastic deaths, lung cancer
was most common (1.5% [16 of 1,078] in the DCB
group and 1.4% [3 of 212] in the PTA group;
p > 0.999), followed by gastrointestinal malignancies
(0.7% [8 of 1,078] in the DCB group and 1.9% [4 of 212]
in the PTA group; p ¼ 0.119).
We analyzed the frequency of SAEs in the LEVANT 2
randomized cohorts as precursors of death, because
new-onset events may not culminate in mortality over
the follow-up observation period. Overall, there were
530 SAEs in the 316 DCB patients (1.7 per patient) and
284 in the 160 PTA patients (1.8 per patient). SAEs were
balanced in the 2 treatment arms (Table 5). SAEs of any
type occurred in 30.4% (96 of 316) of DCB patients
versus 27.5% (44 of 160) of PTA patients (p ¼ 0.525).
Cardiovascular SAEs occurred in 18.0% (57 of 316)
versus 18.1% (29 of 160) patients in the DCB and PTA
treatment arms, respectively (p > 0.999). There were
no significant between-group differences in the rates
of other types of SAEs, with 2 exceptions: gastroin-
testinal SAEs occurred in numerically fewer patients in
the DCB group (6.6% [21 of 316] vs. 12.5% [20 of 160];
p ¼ 0.038), as did peripheral vascular SAEs (32.0% [101
of 316] vs. 40.6% [65 of 160]; p ¼ 0.067).
SUBSET ANALYSES. Using the combined randomized
and Continued Access Registry cohorts of the
LEVANT 2 trial, the results of a stepwise Cox
proportional hazards model for mortality rate in
LEVANT 2 identified the following covariates predic-
tive of mortality: age, left-sided target limb, Ruth-
erford category, angiotensin II receptor blockers at
discharge, prior treatment of the target lesion, anti-
coagulant agents at discharge, arrhythmia at baseline,
and diabetes (Table 6). Dose was not a significant
covariate in the model.
The effect of dose was studied further using quar-
tiles corresponding to increasing doses. No significant
dose-response relationship was identified using the
Cox proportional hazards model when adjusted
for the predictors of mortality identified earlier
(p $ 0.05).
TABLE 4 Adjudicated Causes of Death
DCB Angioplasty PTA p Value
CV deaths 5.1 (55/1,078) 3.8 (8/212) 0.489
Heart failure 1.9 (21/1,078) 1.4 (3/212) 0.784
Acute MI 1.3 (14/1,078) 0.9 (2/212) >0.999
CV hemorrhage 0.1 (1/1,078) 0.0 (0/212) >0.999
Stroke 0.6 (7/1,078) 0.5 (1/212) >0.999
Sudden cardiac death 0.6 (7/1,078) 0.5 (1/212) >0.999
Other 0.5 (5/1,078) 0.5 (1/212) >0.999
Non-CV deaths 7.3 (79/1,078) 5.2 (11/212) 0.304
Neoplasm 4.5 (48/1,078) 3.3 (7/212) 0.577
Blood-based 0.1 (1/1,078) 0.0 (0/212) >0.999
Brain 0.2 (2/1,078) 0.0 (0/212) >0.999
Gastrointestinal 0.7 (8/1,078) 1.9 (4/212) 0.119
Lung 1.5 (16/1,078) 1.4 (3/212) >0.999
Pancreatic 0.1 (1/1,078) 0.0 (0/212) >0.999
Other 1.2 (13/1,078) 0.0 (0/212) 0.143
Undetermined neoplasm 0.2 (2/1,078) 0.0 (0/212) >0.999
Non-neoplasm 2.9 (31/1,078) 1.9 (4/212) 0.642
Hepatobiliary 0.1 (1/1,078) 0.0 (0/212) >0.999
Infection 1.4 (15/1,078) 1.4 (3/212) >0.999
Pulmonary 0.7 (8/1,078) 0.0 (0/212) 0.367
Renal 0.2 (2/1,078) 0.5 (1/212) 0.417
Suicide 0.2 (2/1,078) 0.0 (0/212) >0.999
Trauma 0.2 (2/1,078) 0.0 (0/212) >0.999
Inflammatory 0.1 (1/1,078) 0.0 (0/212) >0.999
Undetermined deaths 1.6 (17/1,078) 1.4 (3/212) >0.999
All deaths 14.0 (151/1,078) 10.4 (22/212) 0.186
Values are % (n/N).
CV ¼ cardiovascular; MI ¼ myocardial infarction; other abbreviations as in Table 1.
TABLE 5 Rates of Adverse Events Between Groups
DCB Angioplasty PTA p Value
Serious adverse events
Cardiovascular 18.0 (57/316) 18.1 (29/160) >0.999
Bleeding 4.1 (13/316) 3.1 (5/160) 0.800
Infection 8.9 (28/316) 7.5 (12/160) 0.727
Malignancy 6.3 (20/316) 4.4 (7/160) 0.530
Arrythmia 2.8 (9/316) 5.0 (8/160) 0.295
Pulmonary 10.4 (33/316) 7.5 (12/160) 0.325
Orthopedic 8.9 (28/316) 10.6 (17/160) 0.619
Gastrointestinal 6.6 (21/316) 12.5 (20/160) 0.038
Peripheral Vascular 32.0 (101/316) 40.6 (65/160) 0.067
Neurological 7.9 (25/316) 5.6 (9/160) 0.452
Any type 30.4 (96/316) 27.5 (44/160) 0.525
Adverse events*
Cardiovascular 45.6 (144/316) 50.0 (80/160) 0.383
Bleeding 13.9 (44/316) 12.5 (20/160) 0.776
Infection 32.0 (101/316) 30.6 (49/160) 0.835
Malignancy 12.3 (39/316) 8.8 (14/160) 0.282
Any type 62.7 (198/316) 66.9 (107/160) 0.419
Values are % (n/N). *Includes serious adverse events.
Abbreviations as in Table 1.
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The effect of reintervention on survival was eval-
uated in the LEVANT 2 randomized trial. DCB patients
who underwent reintervention, either with or
without a paclitaxel device, had a higher 5-year sur-
vival rate (87.8  4.3%) than DCB patients without
reintervention (79.3  2.7%). Similarly, the 5-year
survival rate for PTA patients with reintervention,
paclitaxel or not, was higher than the rate for PTA
patients who did not undergo reintervention
(93.5  4.4% vs. 86.8  3.2%). Reintervention with a
paclitaxel-coated or paclitaxel-eluting device versus
no reintervention was found to increase survival in
the DCB (85.8  5.4% vs. 80.0  2.6%) and PTA
(92.0  5.4% vs. 86.8  3.1%) arms.
When stepwise Cox proportional hazards modeling
was performed with treatment (DCB angioplasty or
PTA) as a covariate, various factors were identified
that were predictive of all SAEs and of specific SAE
types. Treatment with DCB angioplasty or PTA,
however, was not predictive of SAEs in general or for
any specific SAE type.
DISCUSSION
Patient-level data from the Lutonix femoropopliteal
clinical program refute the observations of increased
mortality after DCB angioplasty treatment. Although
numerically increased mortality risk was observed in
the LEVANT 2 randomized trial, the mortality signal
was not statistically significant, paclitaxel did not
appear to be a predictor of mortality in multivariate
analyses, the relationship between dose and risk was
not evident after adjustment for predictors of mortal-
ity from the multivariate analysis, and the signal was
not present in the other LEVANT randomized trials.
Randomized controlled trials for regulatory
approval of DCBs and stents uniformly confirmed the
safety and effectiveness of paclitaxel-containing
interventional devices for femoropopliteal angio-
plasty. Published studies met their pre-determined
primary safety endpoints and showed a 40% reduc-
tion in target lesion reinterventions after DES and
DCB treatment compared with uncoated PTA, a
finding that persisted through 5-year follow-up (8,11).
A study of Medicare beneficiaries also found no dif-
ferences in mortality in patients with PAD treated
with DES or bare-metal stents (4).
The systematic review and meta-analysis of Kat-
sanos et al. (9) found an almost 2-fold increase in the
relative risk for all-cause mortality after treatment
with paclitaxel-containing devices compared with
uncoated PTA for femoropopliteal PAD. It is impor-
tant to note that none of the studies included in the
review by Katsanos et al. (9) were designed to assess
or powered to detect a mortality signal, especially in
the later years of follow-up (12). As such, the observa-
tions should be treated as hypothesis generating only.
The numeric association between paclitaxel and
mortality, although demonstrated in several random-
ized trials, does not confirm causality (6–8,13). In most
randomized trials, the treatment groups are balanced
at the onset. Demographic characteristics, baseline
comorbidities, and the anatomic characteristics of the
target lesions are similar in the 2 treatment arms. The
composition of the analytic dataset may change over
time, however, as patients return for follow-up in a
differential fashion between the 2 treatment arms.
Originally balanced groups may become unbalanced
with respect to comorbidities. Unblinded trials are
especially prone to post-treatment population differ-
ences, as are trials in which the randomized treatment
itself produces differences in patient and physician
behavior. For instance, patient follow-up compliance
may be different when 1 treatment is associated with
marked improvement in effectiveness; patients who
have improvement in symptoms may be less likely to
continue with a protocol-specified follow-up visit
schedule. By contrast, patients who have failed effec-
tiveness, for example, those with target lesion reste-
nosis, may be treated more aggressively for their
systemic atherosclerotic disease with more antiplate-
let and antihyperlipidemic medications or other
medical therapies.
Reintervention itself was protective against mor-
tality. Irrespective of whether patients were in the
DCB or the PTA randomized treatment arm, they were
less likely to die if they underwent reintervention.
The same finding was noted with paclitaxel reinter-
ventions; reintervention with paclitaxel-containing
devices was protective against mortality whether a
patient was in the DCB or PTA randomized treatment
arm.
TABLE 6 Multivariate Analysis of Mortality
Hazard Ratio LCL UCL p Value
Age (per yr) 1.03 1.02 1.05 <0.001
Left-sided target limb 1.55 1.12 2.15 0.009
Rutherford category 1.41 1.08 1.84 0.012
ARB at discharge 0.58 0.37 0.89 0.013
Prior treatment to target lesion 1.67 1.08 2.60 0.022
Anticoagulant agents at discharge 2.13 1.10 4.12 0.025
Arrhythmia at baseline 1.65 1.05 2.61 0.031
Diabetes 1.18 1.00 1.40 0.047
Stepwise Cox proportional hazards stepwise regression, propensity adjusted using stratification,
LEVANT 2 randomized arms and Continued Access Registry cohort.
ARB ¼ angiotensin II receptor blocker; LCL ¼ 95% lower confidence limit; UCL ¼ 95% upper
confidence limit.
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These observations raise the specter of whether the
mortality signal identified by Katsanos et al. (9) and
others is from causation, with paclitaxel causing death
due to a yet undetermined mechanism, or whether the
finding is from a noncausal association with a post-
randomization effect. The criteria of Bradford Hill
were created more than 50 years ago as a paradigm to
identify when an observed association has underlying
causation between treatment and outcome (14). Hill
proposed 9 aspects of association that have become
fundamental tenets of causal inference. The Hill
criteria, as applied to the association between pacli-
taxel femoropopliteal interventions and mortality,
begin with the strength of association. The greater the
strength, the more likely an association is causal. The
Lutonix data demonstrated a weak association be-
tween paclitaxel and death; the HRs overlapped 1 in all
studies. The second criterion, consistency, was also
not upheld. Among the studies, only LEVANT 2 had a
mortality signal, and other studies had a numerically
lower risk for death with DCB angioplasty. The Hill
criterion of specificity (exposure causes the event
through 1 specific pathway) was not evident. There
was no clustering of adverse event types or causes of
SAEs or deaths, as would be expected if paclitaxel ob-
servations were causative through 1 pathway, for
example, through a cardiovascular, neoplastic, or in-
fectious mechanism. Temporality, epidemiologically
themost essential of the criteria, was not evident in the
Lutonix analysis. Events occurred years after pacli-
taxel left the body. The mortality signal becomes
evident several years after paclitaxel is cleared from
the body, but preclinical studies document absence of
paclitaxel in the bloodstream after several hours and
clearance from the arterial wall and organs within a
few months. If an agent causes an event, there should
be a dose-response relationship. Dose was not identi-
fied as a predictor of either adverse events or of mor-
tality in the multivariate analyses performed.
Biological plausibility and coherence were enigmatic,
at least with respect to the current body of knowledge
on paclitaxel’s known molecular mechanisms and its
interaction with other drugs. Despite analyses of the
Lutonix studies and those of others, no known mech-
anism of increased mortality with paclitaxel use has
been elucidated. Experimental manipulation, the
penultimate Hill criterion, is not relevant to DCB trials,
because the duration of exposure cannot be manipu-
lated to ascertain the effect of cessation of treatment
on outcome. The last criterion, that of analogy, is also
not relevant to paclitaxel studies, because there are
few other similar agents that have been studied in this
clinical setting. In summary, although the LEVANT 2
randomized trial had a numerically higher 5-year
mortality rate in its DCB arm, this association did not
satisfy any of the criteria for causation.
STUDY LIMITATIONS. The analyses were limited by
the relatively small sizes of the randomized trials and
the small numbers of patients in the PTA arms, with a
large imbalance in the protocol-defined ratio of DCB
to PTA patients. Baseline covariates and concomitant
medications were limited to those that were antici-
pated to be important for trials with clinically driven
target lesion revascularization as the primary effec-
tiveness endpoint. Dose-response relationships may
be stochastic rather than deterministic and, as such,
would not be detected with the present analysis. Loss
to follow-up may not have occurred at random and
was unbalanced between the 2 treatment arms. The
studies were neither powered for mortality nor able
to accurately assess potential links between
concomitant medications and paclitaxel treatment.
The causes of death were not always evident from the
original medical records. As well, when aggregating
trials or cohorts, no adjustments were made for dif-
ferences in population or treatment effect. Therefore,
there may be measured or unmeasured covariates
that differ among the trials or cohorts that could
affect the findings. Last, the findings of this meta-
analysis may not be generalizable to other commer-
cially available DCBs, as each DCB differs in general
properties, paclitaxel dose, and excipient.
CONCLUSIONS
An analysis of individual patient-level data from the
full LEVANT dataset (LEVANT 1, LEVANT 2, and the
LEVANT Japan Clinical Trial randomized trials as
well as the LEVANT 2 Continued Access Registry)
demonstrated no increase in mortality with the use
of DCBs. The studies were not powered to detect
mortality differences, however, and a larger sample
size with prospective assignment of mortality as an
endpoint would be required to reach a definitive,
more robust conclusion. Although a numeric in-
crease in mortality was observed in the LEVANT 2
DCB randomized treatment arm compared with the
PTA arm, the difference was not statistically signif-
icant. The HR was closer to 1.0 as additional data
from the other trials were aggregated. The associa-
tion between DCB and late mortality does not imply
causality, and mortality differences may be better
explained by the differences in post-randomization
medical treatment in the 2 cohorts, DCB angio-
plasty and PTA. The identification of factors pre-
dictive of mortality after treatment may be due to
chance alone; alternatively, the observed
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associations may arise from associations between
the identified predictor and other, unmeasured
covariates. The beneficial effect of reinterventions
suggests a survival advantage related to more
frequent patient-physician encounters. Further
analysis of existing datasets from clinical trials and
real-world registries may elucidate these findings.
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PERSPECTIVES
WHAT IS KNOWN? Following publication of a
meta-analysis that revealed increased mortality in
patients treated with paclitaxel coated balloons, the
U.S. Food and Drug Administration held an advisory
board meeting to evaluate paclitaxel as an approved
medical therapy. After the meeting, the U.S. Food and
Drug Administration highlighted a need for studies of
better quality with more rigorous data collection
before a decision could be formulated regarding the
paclitaxel devices from 5 manufacturers.
WHAT IS NEW? This publication reports granular
data specific to the Bard Lutonix DCB.
WHAT IS NEXT? While these patient-level data will
help a reader evaluate the Lutonix product in clinical
practice, they will also form a basis for the design of
future studies of paclitaxel devices specifically and
lower extremity interventional devices more
generally.
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